Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Capivasertib in Moderate Hepatic Impairment
NCT07343960Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of capivasertib in cancer (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under concentration time curve from zero to infinity, Area under concentration-curve from time 0 to the last quantifiable concentration and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
capivasertib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07343960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07343960.